Novel mAb contraceptive + TDF IVR

Status

Ongoing

Phase

Pre-clinical

Principal Investigator(s)

BAUM, MARC MICHAEL

Objective

Formulation of a novel, nonhormonal contraceptive agent based on a multivalent monoclonal antibody (mAb) that blocks sperm from swimming through mucus and accessing the egg with antiretroviral (ARV) agents with demonstrated clinical efficacy in preventing HIV in a behavior-monitoring IVR.

Prevention Option(s)

Microbicides

Arms and Assigned Interventions

Mode of Delivery

Ring

Products

TDF

Official Code

Novel mAb contraceptive + TDF IVR

Related Publications

1R01HD101344-01

Trial Sponsors

NICHD

Product Developers

Oak Crest Institute of Science; University of North Carolina Chapel Hill

May 2020

February 2021

You are here

Novel mAb contraceptive + TDF IVR